Fahad Buskandar

Dr. Fahad Buskandar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
KSKumudhavalli Kavanoor Sridhar
Kumudhavalli Kavanoor Sridhar
FBFahad Buskandar
Fahad Buskandar
MDManreet Dhaliwal
Manreet Dhaliwal
GCGordane V. Calloo
Gordane V. Calloo
ABAndrea K Boggild
Andrea K Boggild
Dengue and malaria are common vector-borne tropical diseases and are associated with high morbidity and mortality. Co-infection of dengue and malaria is underestimated due to parsimonious diagnostic approaches once the diagnosis of either is made, particularly using point-of-care assays, such as rapid diagnostic tests (RDTs). We present a case of dengue and Plasmodium vivax co-infection in a returned traveler from an endemic region, in whom the epidemiology and clinical course are highly suggestive of dengue triggering a P. vivax relapse. The literature on the co-occurrence of dengue and malaria in travelers is reviewed, as is the state of knowledge surrounding dengue as a precipitant to relapsing malaria.

30 September 2026 in Transplant Infectious Disease
Verified
Journal Article
Open access
FBFahad Buskandar
Fahad Buskandar
AKAndrew H. Karaba
Andrew H. Karaba
BTBrandon Trollinger
Brandon Trollinger
RARobin K. Avery
Robin K. Avery
Background: Norovirus can cause devastating, chronic diarrhea in immunocompromised individuals. There is no approved therapy for this infection. Case series have described oral immunoglobulin (Ig) as a treatment option, but destruction by gastric enzymes may affect efficacy. This study reviews clinical outcomes and safety of enteral Ig given via post‐pyloric nasoduodenal tube in solid organ transplant recipients (SOTRs) with chronic norovirus‐related diarrhea. Methods: All cases of chronic norovirus‐related diarrhea in SOTRs managed with enteral Ig at our center were retrospectively reviewed. Enteral Ig was prepared from the intravenous Ig (IVIg) product and dosed at 50 mg/kg/dose every 6 h for 48 h. The primary outcome was resolution of diarrhea at 100 days; the secondary outcome was recurrence of norovirus‐related diarrhea within 1 year. Results: Seven SOTRs (five kidney, one kidney/pancreas, and one double lung recipient) with chronic norovirus‐related diarrhea who received enteral Ig were identified. All patients had previously failed treatment with nitazoxanide, 28% had failed prior IVIg, and 80% had mycophenolate held without improvement. Diarrhea resolved in all patients following enteral Ig without documented recurrence, with median time to resolution of 21 days (IQR: 10–50). Adverse events included nausea and vomiting in one patient. Conclusion: Our small size and single‐center study suggests that enteral Ig given via a nasoduodenal tube may be further evaluated as a potential approach for chronic norovirus infection in SOTRs. Large randomized controlled trials with symptom diaries to assess time to resolution more accurately, and serial stool nucleic acid testing, will be needed for confirmation. image